GLP-1 weight-loss medications represent one of the most significant biotech advancements of the last decade, yet clinical psychologists warn they could act as a dangerous trigger for eating disorders. A comprehensive report published in JAMA Psychiatry indicates that the global incidence of anorexia nervosa and bulimia nervosa jumped by 71% between 1990 and 2023. By the end of 2023, approximately 18.1 million people worldwide were living with one of these two conditions, a figure researchers predict could rise to 21.8 million by 2050.
The study, led by Ruhai Bai from the Children's Hospital of Nanjing Medical University, analyzed data from 204 countries and territories. The findings highlight a severe impact on global health, estimating that these disorders cost the world the equivalent of 3.83 million years of healthy life in 2023 alone. While population growth contributes to these numbers, it does not fully explain the sharp increase. Experts suggest that environmental factors, particularly social media algorithms and pandemic-related isolation, have played a significant role. Research from the University of Melbourne found that TikTok users with eating disorders were exposed to over 4,300% more toxic content related to dieting and body image than those without such conditions.
Cheri Levinson, a clinical psychologist at the University of Louisville, reports witnessing the most severe symptoms in her nearly 20-year career. She notes that many patients are now misusing GLP-1 drugs, with some children as young as eight or nine developing disorders. A small study by Levinson's team found that 30% of individuals with eating disorders had used these medications, and 10% appeared to be misusing them. Levinson believes the true prevalence of misuse is likely higher, noting that patients are obtaining drugs through compound pharmacies or dubious online sources.
Cynthia Bulik, a psychologist at the University of North Carolina, expresses concern that GLP-1s could accelerate weight loss in individuals with anorexia, leading to more advanced and difficult-to-reverse stages of illness. In response to these emerging risks, new clinical guidelines recommend that doctors screen patients for eating disorders before prescribing these drugs. The guidelines also emphasize the need for better patient education and robust monitoring for those taking GLP-1 medications. While the study did not explicitly explore the causes of the rise, experts agree that the combination of social pressure, digital exposure, and increased access to potent weight-loss drugs is creating a worsening public health scenario.
Sources: MIT Technology Review.